Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
6.80
-0.29 (-4.09%)
At close: Apr 28, 2026, 4:00 PM EDT
6.85
+0.05 (0.74%)
After-hours: Apr 28, 2026, 6:05 PM EDT
Cartesian Therapeutics Employees
Cartesian Therapeutics had 75 employees as of December 31, 2025. The number of employees increased by 9 or 13.64% compared to the previous year.
Employees
75
Change (1Y)
9
Growth (1Y)
13.64%
Revenue / Employee
$37,293
Profits / Employee
-$1,737,360
Market Cap
180.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75 | 9 | 13.64% |
| Dec 31, 2024 | 66 | 28 | 73.68% |
| Dec 31, 2023 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Protalix BioTherapeutics | 226 |
| Humacyte | 184 |
| Tonix Pharmaceuticals Holding | 142 |
| Precision BioSciences | 68 |
| Acumen Pharmaceuticals | 61 |
| Korro Bio | 58 |
| Corbus Pharmaceuticals Holdings | 36 |
RNAC News
- 26 days ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 3 months ago - Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook - GlobeNewsWire
- 4 months ago - Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors - GlobeNewsWire
- 7 months ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 8 months ago - Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 11 months ago - Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - GlobeNewsWire
- 1 year ago - Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - GlobeNewsWire